蛋白磷酸酶2A细胞抑制剂、bcl-2及p63在甲状腺乳头状癌中的表达及其意义  

Expression of CIP2A, bcl-2 and p63 in papillary thyroid cancer and their significances

作　　者：裴彩丽[1] 武丽娜[2] 郑绘霞[2] 梁建芳[2] 张国恒[3] Pei Caili Wu Lina Zheng Huixia Liang Jianfang Zhang Guoheng(Graduate School of Shanxi Medical Univercity, Taiyuan 030001, China Department of Pathology, the First Affiliated Hospital of Shanxi Medical Univereity, Taiyuan 030001, Chin Department of Laboratory, the First Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China)

机构地区：[1]山西医科大学研究生学院,太原030001 [2]山西医科大学第一医院病理科,太原030001 [3]山西医科大学第一医院检验科,太原030001

出　　处：《肿瘤研究与临床》2017年第5期322-326,共5页Cancer Research and Clinic

摘　　要：目的 探讨蛋白磷酸酶2A细胞抑制剂（CIP2A）、bcl-2、p63在甲状腺乳头状癌（PTC）中的表达及其意义.方法 选择有完整临床病理资料且术前未经治疗的手术切除甲状腺肿瘤存档蜡块标本117例,其中结节性甲状腺肿（NG）30例,甲状腺腺瘤（TA）30例,PTC 57例[经典甲状腺乳头状癌（cPTC）20例,微小甲状腺乳头状癌（PMC）20例,滤泡性甲状腺乳头状癌（FPTC）7例].应用免疫组织化学方法检测各组中CIP2A、bcl-2、p63表达情况.结果 CIP2A在NG组、TA组和PTC组中阳性率分别为0、0和94.74%（54/57）,差异有统计学意义（χ2=105.56,P〈0.05）;bcl-2在NG组、TA组和PTC组中阳性率分别为16.67%（5/30）、13.33%（4/30）和85.96%（49/57）,差异有统计学意义（χ2=58.95,P〈0.05）;p63在各组中阳性率分别为6.67%（2/30）、3.33%（1/30）、5.26%（3/57）,差异无统计学意义（χ2=0.35,P〉0.05）;CIP2A和bcl-2在PTC组的阳性率明显高于NG组和TA组,差异均有统计学意义（χ2=105.56,P=0.00;χ2=58.95,P=0.00）.Spearman相关分析显示,CIP2A高表达与bcl-2表达具有相关性（r=0.94,P=0.00）.CIP2A、bcl-2、p63在各PTC亚型中表达差异无统计学意义（χ2值分别为2.02、2.64、1.85,均P〉0.05）.CIP2A、bcl-2和p63的表达与患者年龄、性别、发病部位、淋巴结转移等临床参数无关（均P〉0.05）.结论 CIP2A、bcl-2的表达与PTC相关,且PTC中CIP2A高表达与bcl-2的表达相关.p63的表达与PTC无相关性.Objective To investigate the expression and significance of cellular inhibitor of protein phosphatase 2A （CIP2A）, bcl-2 and p63 in papillary thyroid cancer （PTC）. Methods Using immunohistochemistry to detect the expression of CIP2A, bcl-2 and p63 in 30 cases of nodular goiter （NG）, 30 cases of thyroid adenoma （TA） and 57 cases of PTC [including classical PTC （cPTC） 20 cases, papillary microcarcinoma （PMC） 20 cases, follicular thyroid papillary carcinoma （FPTC） 7 cases]. Results In NG group, TA group and PTC group, positive rates of CIP2A were 0, 0 and 94.74 % （54/57）, respectively. The differences were statistically significant. In NG group, TA group and PTC group, positive rates of bcl-2 were 16.67 % （5/30）, 13.33 % （4/30） and 85.96 % （49/57）, respectively. The differences were statistically significant. In each group, positive rates of p63 were 6.67% （2/30）, 3.33% （1/30） and 5.26% （3/57）, respectively, no significant difference among them. In PTC, expression of CIP2A and bcl-2 were significantly higher than in NG and TA （χ2 = 105.56, P= 0.00; χ2 = 58.95, P= 0.00）. Furthermore, the expression of CIP2A and bcl-2 had correlation in PTC （r=0.94, P=0.00）. The expression of CIP2A, bcl-2 and p63 had no significantly difference among all the PTC subtype （χ2 values were 2.02, 2.64, 1.85; all P〉 0.05）. The expression of CIP2A, bcl-2 and p63 was not associated with patients＆#39;age, sex, site, lymph node metastasis （all P〉0.05）. Conclusions High expression of CIP2A and bcl-2 is associated with PTC, and the expression of CIP2A and bcl-2 has correlation in PTC. The expression of p63 has no correlation with PTC.

关 键 词：甲状腺肿瘤 乳头状瘤 蛋白磷酸酶2A细胞抑制剂 BCL-2 P63 

分 类 号：R736.1[医药卫生—肿瘤]